Biopharma IPR filing at the PTAB smashes record in 2017
Group 1600 patent challenges at the Patent Trial and Appeal Board hit an all-time high last year, reveals a report from Fish & Richardson. This included a “dramatic increase” in IPRs challenging biologic drug patents
Post-grant petitions in the biopharma space reached an all-time high in 2017, according to Fish & Richardson’s Post-Grant 2017 Report.
The law firm defines petitions in the biopharma space as those involving Group 1600 patents. It said that of...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.